Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Recordati Acquires Six OTC Products

European pharmaceutical group Recordati Tuesday announced the acquisition of the marketing authorizations, the trademarks and additional assets concerning six OTC pharmaceuticals for Germany from Cilag GmbH International and McNeil GmbH & Co. oHG.

The products acquired are JHP-Rödler, BetadormD, Rhinopront, Collomack Topical, Tirgon and Xitix. The 2012 sales for the six products are estimated at around EUR 6 million.

Giovanni Recordati, chairman and CEO of the Recordati Group, said, "The OTC pharmaceutical segment in Germany represents 52 percent share in units of the overall pharmaceutical market."

Recordati added that together with the existing OTC portfolio, the German subsidiary will now be able to better exploit the OTC market potential by building a dedicated sales organization.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Stocks moved notably higher over the course of the trading day on Friday after initially showing a lack of direction. The gains on the day extended the recent upward trend by the markets, with the tech-heavy Nasdaq reaching its best closing level in almost a month. Looking to capitalize on news of an Ebola diagnosis in New York City, Republican Senate candidate Scott Brown issued a statement Friday criticizing his Democratic opponent Sen. Jeanne Shaheen, D-N.H., for "waffling" on a travel ban. In another troubling sign for Democrats, the results of a Gallup poll released on Friday show that Tea Party Republicans are much more motivated to vote in the upcoming midterm elections than other Americans. The poll found that 73 percent of Tea Party Republicans are "extremely" or "very" motivated to vote in this year's elections.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.